TY - JOUR
T1 - Human wild-type tau interacts with wingless pathway components and produces neurofibrillary pathology in Drosophila
AU - Jackson, George R.
AU - Wiedau-Pazos, Martina
AU - Sang, Tzu Kang
AU - Wagle, Naveed
AU - Brown, Carlos A.
AU - Massachi, Sasan
AU - Geschwind, Daniel H.
N1 - Funding Information:
We thank V.M.-Y. Lee for the htau4R cDNA; E. Siegfried, B. Hay, and the Bloomington Stock Center for fly strains; P. Fisher for the lamin antibody; Z. Luo for excellent technical support; and B. Sjöstrand for assistance with TEM. The elav monoclonal antibody was obtained from the Developmental Studies Hybridoma Bank developed under the auspices of NICHD and maintained by the University of Iowa. We also thank Larry Zipursky for critical comments on the manuscript and Dr. Robert Collins for his support of the Neurogenetics program. This work was supported by the NINDS (G.R.J.) the John Douglas French Alzheimer Foundation (D.H.G., M.W.-P.), the UCLA Neurogenetics program (G.R.J., D.H.G.), and the NIA-funded UCLA Alzheimer's Disease Research Center (G.R.J., D.H.G.).
PY - 2002/5/16
Y1 - 2002/5/16
N2 - Pathologic alterations in the microtubule-associated protein tau have been implicated in a number of neurodegenerative disorders, including Alzheimer's disease (AD), progressive supranuclear palsy (PSP), and frontotemporal dementia (FTD). Here, we show that tau overexpression, in combination with phosphorylation by the Drosophila glycogen synthase kinase-3 (GSK-3) homolog and wingless pathway component (Shaggy), exacerbated neurodegeneration induced by tau overexpression alone, leading to neurofibrillary pathology in the fly. Furthermore, manipulation of other wingless signaling molecules downstream from shaggy demonstrated that components of the Wnt signaling pathway modulate neurodegeneration induced by tau pathology in vivo but suggested that tau phosphorylation by GSK-3β differs from canonical Wnt effects on β-catenin stability and TCF activity. The genetic system we have established provides a powerful reagent for identification of novel modifiers of tau-induced neurodegeneration that may serve as future therapeutic targets.
AB - Pathologic alterations in the microtubule-associated protein tau have been implicated in a number of neurodegenerative disorders, including Alzheimer's disease (AD), progressive supranuclear palsy (PSP), and frontotemporal dementia (FTD). Here, we show that tau overexpression, in combination with phosphorylation by the Drosophila glycogen synthase kinase-3 (GSK-3) homolog and wingless pathway component (Shaggy), exacerbated neurodegeneration induced by tau overexpression alone, leading to neurofibrillary pathology in the fly. Furthermore, manipulation of other wingless signaling molecules downstream from shaggy demonstrated that components of the Wnt signaling pathway modulate neurodegeneration induced by tau pathology in vivo but suggested that tau phosphorylation by GSK-3β differs from canonical Wnt effects on β-catenin stability and TCF activity. The genetic system we have established provides a powerful reagent for identification of novel modifiers of tau-induced neurodegeneration that may serve as future therapeutic targets.
UR - http://www.scopus.com/inward/record.url?scp=0037118247&partnerID=8YFLogxK
U2 - 10.1016/S0896-6273(02)00706-7
DO - 10.1016/S0896-6273(02)00706-7
M3 - Article
C2 - 12062036
AN - SCOPUS:0037118247
SN - 0896-6273
VL - 34
SP - 509
EP - 519
JO - Neuron
JF - Neuron
IS - 4
ER -